Long-term consequences of osteoporosis therapy with denosumab

Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandeira, Francisco, de Oliveira, Lucian Batista, Bilezikian, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118828/
https://www.ncbi.nlm.nih.gov/pubmed/36382761
http://dx.doi.org/10.20945/2359-3997000000560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118828/
https://www.ncbi.nlm.nih.gov/pubmed/36382761
http://dx.doi.org/10.20945/2359-3997000000560

Ejemplares similares